ReferenceID 6230
Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice
Phytother Res
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by the accumulation of triglycerides and associated with obesity, hyperlipidemia and insulin resistance. Currently, there is no therapy fo
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 6230
- Evidence Id
- 22820
- Core Evidence Id
- 22820
- Source Reference Id
- 5738
- Herb2 Reference Id
- HBREF006535
- Subject Paper Key
- HBIN044393_32592532
- Pubmed Id
- 32592532
- Doi
- 10.1002/ptr.6747
- Paper Title
- Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice
- Paper Abstract
- Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by the accumulation of triglycerides and associated with obesity, hyperlipidemia and insulin resistance. Currently, there is no therapy for NAFLD. Emerging evidences suggest that the inhibition of liver X receptor (LXR) activity may be a potential therapy for hepatic steatosis. Here, we identified that sophoricoside is a selective antagonist of LXRbeta. Sophoricoside protected against obesity and glucose tolerance, and inhibited lipid accumulation in the liver of high-fat diet-induced obesity (DIO) mice and methionine and choline-deficient diet-induced nonalcoholic steatohepatitis mice. Furthermore, sophoricoside inhibited malondialdehyde, and increased superoxide dismutase and glutathione in the liver of the mice. In HepG2 cells, pretreatment with sophoricoside rescued GSH concentration decrease induced by H2 O2 treatment. Our data suggest that sophoricoside is a novel LXRbeta selective antagonist and may improve glucose and lipid dysfunction, and attenuate lipid accumulation in the liver of DIO mice via anti-oxidant properties, which may be developed as a therapy for NAFLD.
- Journal
- Phytother Res
- Publish Year
- 2020
- Experiment Subject
- mouse; hepg2 cells
- Experiment Type
- Cell Experiment
- Phenotype Related
- High-fat Diet-induced Obesity; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Chronic Liver Disease; Hepatic Steatosis; Obesity; Hyperlipidemia
- Paper Title Cn
- Paper Title En
- Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice
- Bilingual Status
- semi_complete